Samsung Biologics Obtains 3 ISO Certifications... Information Security and Anti-Corruption

Incheon Songdo Samsung Biologics Plant 3 Exterior View

[Asia Economy Reporter Chunhee Lee] Samsung Biologics announced on the 13th that it has been awarded a total of three international standard certifications from the International Organization for Standardization (ISO): ▲ISO 27001 (Information Security Management System), ▲ISO 27017 (Cloud Service Information Security Management System), and ▲ISO 37001 (Anti-Bribery Management System).

Samsung Biologics renewed its ISO 27001 certification, which it first obtained in the industry in 2019, and newly acquired ISO 27017, thereby gaining recognition for its global-level security management system. In particular, the ISO 27017 certification enhances the protection of customer information in cloud environments amid accelerated digital transformation. Samsung Biologics is the only company in the Contract Development and Manufacturing Organization (CDMO) industry to have obtained both the highest authority information security international standards, ISO 27001 and ISO 27017.

Additionally, Samsung Biologics obtained the anti-bribery management system ISO 37001 certification for all business sectors, demonstrating its compliance management and anti-corruption capabilities. Due to the nature of the CDMO business, Samsung Biologics receives all product-related information from clients before production begins. This information includes specific data necessary for product development and technologies for mass production, encompassing core client information. Therefore, information security capabilities and ethical management systems are considered essential elements for CDMO companies.

Samsung Biologics explained that acquiring these three global ISO international standards simultaneously will further enhance the trust of its global clients.

Meanwhile, Samsung Biologics also received the industry’s first ‘Excellence Award for Integrated Management System Award’ on the same day. This award is given by BSI, which selects companies based on international standard requirements.

BSI cited as the reason for the award that Samsung Biologics manages and holds certifications in a total of eight areas, starting with ISO 22301 (Business Continuity Management), followed by ISO 27001, ISO 14001 (Environmental Management), ISO 45001 (Occupational Health and Safety), ISO 50001 (Energy Management), ISO 9001 (Quality Management), ISO 27017, and ISO 37001, all in accordance with international standard requirements.

John Rim, President of Samsung Biologics, stated, “We will do our best in ESG (Environmental, Social, and Governance) management to meet social expectations regarding the role and responsibility of companies and to satisfy the demands of stakeholders.”

This content was produced with the assistance of AI translation services.